Journal of the National Comprehensive Cancer Network : JNCCN · 2013
Chronic Myelogenous Leukemia, Version 1.2014.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
O'Brien Susan, Radich Jerald P, Abboud Camille N, Akhtari Mojtaba, Altman Jessica K, Berman Ellin, DeAngelo Daniel J, Deininger Michael, Devine Steven, Fathi Amir T, Gotlib Jason, Jagasia Madan, Kropf Patricia, Moore Joseph O, Pallera Arnel, Pinilla-Ibarz Javier, Reddy Vishnu Vb, Shah Neil P, Smith B Douglas, Snyder David S, Wetzler Meir, Gregory Kristina, Sundar Hema, Ntational comprehensive cancer network
Аннотация
The 2014 NCCN Clinical Practice Guidelines in Oncology for Chronic Myelogenous Leukemia recommend quantitative reverse-transcription polymerase chain reaction (QPCR) standardized to International Scale (IS) as the preferred method for monitoring molecular response to tyrosine kinase inhibitor (TKI) therapy. A BCR-ABL1 transcript level of 10% or less (IS) is now included as the response milestone at 3 and 6 months. Change of therapy to an alternate TKI is recommended for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with imatinib. Continuing the same dose of TKI or switching to an alternate TKI are options for patients with BCR-ABL1 transcript levels greater than 10% (IS) at 3 months after primary treatment with dasatinib or nilotinib. The guidelines recommend 6-month evaluation with QPCR (IS) for patients with BCR-ABL1 transcript levels greater than 10% at 3 months. Monitoring with QPCR (IS) every 3 months is recommended for all patients, including those who meet response milestones at 3, 6, 12, and 18 months (BCR-ABL1 transcript level ≤10% [IS] at 3 and 6 months, complete cytogenetic response at 12 and 18 months).